Endometrial cancer mortality is rising, making it one of the few cancers with both increasing incidence and death rates. Patients with advanced or recurrent disease continue to face limited treatment options and poor outcomes, driving significant development in these settings. Platinum-based chemotherapy remains foundational to treatment, but immune checkpoint inhibitors have substantially reshaped the treatment landscape, particularly in the frontline setting. Current development efforts span immunotherapy combinations, antibody-drug conjugates (ADCs), and targeted therapies.
Oncology Resource Group (ONCrg) is a team of expert analysts who rigorously evaluate the latest corporate reports, news, and data presentations to distill out important advances in complex therapeutic areas. Our comprehensive medical congress coverage, and continuous market surveillance put these advances into the context of an overarching competitive landscape in endometrial cancer to help guide strategic and tactical commercial development decisions for market participants.









